Top 10 Pharma Companies in World 2018

Posted in Top Brand Lists, Total Reads: 2149

Pharmaceutical industry has been one of the most consistently growing sector the world over. With billions of dollars riding on the medical industry, pharma companies have been regularly huge sums on research & development to have more innovative solutions in medical sciences. The leading companies in the pharma sector has a strong production and distribution of medicines, which are available at all hospitals & pharmacy stores worldwide. The best pharmaceutical companies innovate and product life saving medicines to support healthcare efforts across the world. The list of top pharma companies include names like Pfizer, Roche, Johnson & Johnson followed by Merck, Sanofi, Novartis, AbbVie etc. Here is a list of the top 10 pharma companies in the world 2018.

Quick Glance :

Below are the top Pharmaceuitical Companies in World 2018:

1st Place : Pfizer

2nd Place : Roche

3rd Place : Johnson & Johnson

4th Place : Merck & Co

5th Place : Sanofi

6th Place : Novartis

7th Place : AbbVie

8th Place : GlaxoSmithKline

9th Place : Gilead Sciences

10th Place : Amgen

For More details about rankings and parameters, read on.

Top Pharma Companies 2018 with Ranking Parameters (Revenue, R&D etc):

10. Amgen

Amgen Inc is an American multinational biopharmaceutical organization headquartered in Thousand Oaks, California.

Image: Wikimedia

Amgen finds and creates inventive treatments in both biopharmaceuticals and little particle drugs. In 2017, top 3 of the line drugs incorporate Enbrel, Neulasta, and Aranesp, and for the final quarter, add up to incomes diminished 3 percent versus the final quarter of 2016 to ~6 billion.


For the entire year, add up to incomes diminished 1 percent to 22.8 billion. Generally accepted accounting principles misfortune per offer of 5.89 for the final quarter and GAAP profit per share aka Earnings per share of 2.69 for the entire year incorporate a 6.1 billion charge identified with effects of corporate expense change. Non-GAAP Earnings per share were level in the final quarter at 2.89, driven by higher working edges and intrigue wage and a lower share tally. Free income for the entire year grew 9 percent to 10.5 billion, driven by higher working salary and great changes in working capital. At year end, money and speculations totaled 41.7 billion. The Company hopes to expand speculations to drive extra volume-driven development of novel meds in extensive patient populaces. These designs incorporate another U.S. producing plant. Money to investors totaled 6.5 billion of every 2017 through profits and offer repurchases. The Company's Board of Directors approved an extra 10 billion of offer to repurchases. This approval is not withstanding the current 4.4 billion in share repurchase approval as of 2017. 2018 aggregate incomes direction of 21.8-22.8 billion.

Revenue (USD Million): 22849

R&D Expenses (USD Million): 3562

Annual Revenue Growth: -1%

Looking for Similar Lists, Browse more Top Lists

Share this Page on:
Facebook ShareTweetShare on G+Share on Linkedin